Vaccinex Inc Stock Price, News & Analysis

Vaccinex, Inc. (Nasdaq: VCNX) announced a poster presentation for its research on combination immunotherapy and HTT-lowering in humanized HD mice at the 17th Annual HD Therapeutics Conference on March 2, 2022. The presentation, led by Dr. Amber Southwell, will explore the efficacy of pepinemab in treating Huntington's disease by inhibiting semaphorin 4D (SEMA4D). The conference serves as a platform for advancing research in neurodegenerative diseases. Detailed presentation information and links are available on the company’s website.

Vaccinex announces a stock purchase agreement on January 27, 2022, with existing and new investors for a private placement of 5,945,943 shares at $1.11 per share, yielding approximately $6.6 million. This funding is part of a total of $10.1 million in new equity financing for January 2022. The proceeds will support the development of pepinemab, its lead drug candidate for cancer and neurodegenerative diseases. The placement is expected to close by January 31, 2022, and includes a registration rights agreement with investors.

Vaccinex, a clinical-stage biotechnology firm, announced positive interim results from the Phase Ib segment of the KEYNOTE-B84 study, featuring its drug pepinemab combined with Merck's KEYTRUDA for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Of three patients, two achieved a complete response (CR), despite low PD-L1 biomarker levels. The recommended dose of pepinemab was well tolerated, allowing the continuation of treatment.

Vaccinex plans to expand the trial, enrolling up to an additional 62 patients, and aims to share further findings at a medical conference in 2022.

Vaccinex, Inc. (Nasdaq: VCNX) announced positive interim safety data from the Phase 1b segment of the KEYNOTE B84 study, evaluating the combination of pepinemab and Keytruda in advanced head and neck cancer patients. The safety run-in phase confirmed that pepinemab (20 mg/kg) and Keytruda (200 mg Q3W) were well tolerated, paving the way for the Phase 2 expansion segment, which will enroll up to 62 subjects. This study aims to assess the Objective Response Rate (ORR) and other key metrics, with interim results expected in the second half of 2022.

Vaccinex, Inc. (Nasdaq: VCNX) has announced that Dr. Elizabeth Evans will present a Phase 1/2 study on pepinemab in combination with pembrolizumab for advanced head and neck cancer at the SITC Annual Meeting from November 12-14, 2021. The presentation, Poster #434, will highlight the potential of pepinemab in enhancing treatment efficacy. The poster will be showcased in-person and virtually, with virtual access available until January 9, 2022. Vaccinex aims to leverage its unique drug discovery platform to expand its therapeutic pipeline, particularly in cancer and neurodegenerative diseases.

Vaccinex, Inc. (Nasdaq: VCNX) announces a live presentation by Terrence Fisher, Ph.D., at the Clinical Trials on Alzheimer's Disease Meeting in Boston on November 11, 2021. The presentation will focus on the potential of pepinemab, a SEMA4D-blocking antibody, as a novel treatment for neurodegenerative diseases, supported by clinical proof of concept in Huntington's Disease. Vaccinex aims to leverage its proprietary ActivMAb® platform for future drug development. Further details about the presentation can be found on the company’s website.

Vaccinex, Inc. (Nasdaq: VCNX) has launched clinical trials for its drug pepinemab, targeting advanced recurrent head and neck cancer and Alzheimer’s disease. The Phase 1b/2 trial in head and neck cancer will assess the combination with KEYTRUDA® and aims to enroll 65 subjects, with results expected in H2 2022. The Alzheimer’s study has begun enrollment for 40 subjects, with topline data anticipated in late 2022 or early 2023. Financially, R&D expenses decreased significantly to $3.6 million from $7.3 million year-over-year, while cash reserves increased to $13.8 million.

Vaccinex (Nasdaq: VCNX) announced a virtual presentation by CEO Dr. Maurice Zauderer at the 12th Annual Jefferies London Healthcare Conference on November 18-19, 2021. Investors are invited for one-on-one meetings during this period. The presentation will be accessible from 8:00 am GMT on November 18 until 5:00 pm GMT on November 19. Additionally, the presentation and a replay will be available on Vaccinex's website post-event. The company is focused on treating cancer and neurodegenerative diseases through SEMA4D inhibition, with its lead candidate, pepinemab, currently in clinical evaluation.

Vaccinex, Inc. (Nasdaq: VCNX) announced on November 1, 2021, that Dr. Maurice Zauderer will present at the Virtual Huntington Study Group Meeting on November 5. His presentation will discuss a positive post-hoc subgroup analysis from the SIGNAL Phase 2 trial of pepinemab, indicating cognitive benefits for patients with mildly advanced Huntington's Disease (HD). Dr. Elizabeth E. Evans will also present a related poster. Vaccinex is focused on advancing pepinemab, targeting both neurodegenerative diseases and cancer.